Monitor whether Baggett increases his stake or files a 13D, which would signal activist intent. The company's ongoing strategic review with Lucid Capital Markets (sale or merger process) makes this insider stake potentially relevant to deal dynamics.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $2.49entry
- T+1 · 21h ago −14.06%α −12.14% · $2.14
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Benjamin Matthew Wall Baggett filed a Schedule 13G disclosing beneficial ownership of 250,000 shares of Longeveron Inc. Class A common stock, representing a 7.7% passive stake. This is a new filing by an individual investor, not a fund, and certifies no intent to influence control. The filing follows the company's Q3 earnings miss and strategic review announcement, and comes one week after Millennium Management fully exited its position.
Key Financial Metrics
Key Facts
- Benjamin Matthew Wall Baggett filed a new Schedule 13G reporting 250,000 shares of Longeveron Inc. Class A common stock.
- The stake represents 7.7% of shares outstanding.
- The filing certifies passive intent under Rule 13d-1(c) with no purpose of changing or influencing control.
- The filing date is November 13, 2026, with beneficial ownership as of November 12, 2026.
- This is a new filing, not an amendment to a prior 13G.
- Millennium Management fully exited its Longeveron position as of a November 6, 2026 13G/A filing.
Financial Impact
7.7% stake in a company with $11M market cap, valued at approximately $847,000 based on market cap.
Risk Factors
- Passive certification could be converted to active (13D) if Baggett engages with management or seeks board representation.
- Company has only $7.2M cash and expects operations to fund only into Q1 2027, creating financing risk.
- ELPIS II Phase 2b trial in HLHS missed primary endpoint, and the company is exploring a sale or merger.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0002163771-26-000001 |
| Document: 0002163771-26-000001-index.html | 0002163771-26-000001 |
| Document: 0002163771-26-000001.txt | 0002163771-26-000001 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Viewing Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers